Publication Topic

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, et al. 2022. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy in France. Mol Gene Metab 135(2):S93; doi: 10.1016/j.ymgme.2021.11.242.

Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. 2021. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 9:2050312120986733; doi: 10.1177/2050312120986733. PMID: 33505698.

Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N, Kautz S, Cyr P. Impact of INP104 on healthcare resource use among patients in STOP 301. Presentation at American Academy of Neurology Annual Meeting, Virtual, April 2021.

Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N, Kautz S, Cyr P. INP104 reduces self-reported ED and urgent care in patients with episodic migraine. Presentation at Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Virtual, April 2021.

Sheshadri A, Sacks NC, Healey B, Raza S, Cyr P, Boerner G, Huang HJ. A descriptive analysis of costs and healthcare resource use in patients with bronchiolitis obliterans syndrome (BOS) following lung transplantation. Poster presentation, ISPOR 25th Annual International Meeting, May 2021.

Wallace E, Sacks NC, Cyr P, Baker-Wagner M. An observational cohort analysis on the economic impact of chronic kidney disease in patients with fabry disease. Poster presentation, ISPOR Annual International Meeting, Virtual, May 2021.

Sacks NC, Healey B, Cyr PL, Slocomb T, James E, Beggs A, Graham RJ. Healthcare resource use and expenditures in patients with x-linked myotubular myopathy (XLMTM). Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, April 2021.

Panattoni L, Hernandez J, Liu Y, Sacks NC, Higham R, Stephenson B, Armstrong A. Initial treatment patterns for newly diagnosed, commercially insured patients with psoriasis. Poster presentation, ISPOR, April 2021.

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.